Tarsus Pharmaceuticals Inc (TARS)
EBITDA Growth
28.15%
Quarterly · Period ending:
TARS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported28.15%period ending
Latest reported28.15%period ending
TARS Quarterly EBITDA YoY % (-1454.07% → 28.15%)
Year-over-year change
High-resolution chart · PNG
TARS ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 28.1521% | |
| 69.9113% | |
| 82.0462% | |
| 41.1097% | |
| 42.9675% | |
| 34.8947% | |
| 49.788% | |
| 45.663% | |
| -1.6926% | |
| -52.1536% | |
| -216.6992% | |
| -74.3943% | |
| -495.7901% | |
| -13.9839% | |
| 13.2005% | |
| -36.8537% | |
| -178.5813% | |
| -284.8786% | |
| -29.0286% | |
| -57.7049% | |
| 300.2157% | |
| 611.3172% | |
| -973.8967% | |
| -1,454.0707% |